{"gene":"PRKACB","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2018,"finding":"A somatic missense mutation p.S54L in PRKACB impairs formation of type I PKA holoenzymes and renders them highly sensitive to cAMP. The mutant enzyme shows higher basal PKA activity but lower maximal activity compared to wild-type, as measured by BRET, surface plasmon resonance, and phosphorylation of a synthetic substrate, demonstrating that residue Ser54 is critical for holoenzyme assembly and regulation.","method":"Bioluminescence resonance energy transfer (BRET), surface plasmon resonance, in vitro PKA activity assay with recombinant proteins","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical methods (BRET, SPR, kinase assay) with recombinant proteins in a single rigorous study","pmids":["29669941"],"is_preprint":false},{"year":2020,"finding":"Heterozygous germline or mosaic missense variants in PRKACB lead to PKA holoenzymes with increased sensitivity to activation by cAMP. Expression of PRKACB variants in NIH 3T3 fibroblasts inhibited hedgehog signaling, providing a mechanistic basis for the developmental defects (atrioventricular septal defect, postaxial polydactyly) observed in affected individuals.","method":"Structural and functional analysis of variants, cAMP-sensitivity assays, hedgehog signaling reporter assay in NIH 3T3 fibroblasts","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1-2 — multiple computational and experimental approaches including functional holoenzyme assays and cellular signaling readout","pmids":["33058759"],"is_preprint":false},{"year":2020,"finding":"PRKACB variants p.K286del and p.T300M were identified in subjects with unusual bone and endocrine phenotypes. The p.K286del variant affected PRKACB protein stability and led to increased PKA signaling, while p.T300M did not affect protein stability or response to cAMP.","method":"Functional studies of recombinant variants: protein stability assays, PKA signaling assays","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 — functional characterization of specific variants with stability and signaling assays, single lab","pmids":["33055300"],"is_preprint":false},{"year":2019,"finding":"PRKACB forms recurrent fusion genes (ATP1B1-PRKACB) in intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct, and these fusions are also present in corresponding invasive carcinomas, establishing PRKACB gene rearrangement as a driver event in these tumors.","method":"RNA-based targeted sequencing, RT-PCR, DNA sequencing","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — systematically identified in 20+ IOPNs with matched controls across multiple tissue types, replicated in subsequent studies","pmids":["31678302"],"is_preprint":false},{"year":2013,"finding":"Overexpression of PRKACB in NSCLC cell line LTEP-A2 decreased proliferation, colony formation, and invasion while increasing apoptosis, establishing PRKACB as a functional suppressor of tumor cell growth in this context.","method":"Plasmid transfection/overexpression, MTT assay, colony formation assay, flow cytometry, Transwell invasion assay","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 3 — defined cellular phenotype with multiple assays but single lab, no pathway mechanistic detail","pmids":["23833645"],"is_preprint":false},{"year":2017,"finding":"TAL1 together with hematopoietic transcription factors RUNX1 and GATA1 binds the promoter of the PRKACB isoform 3 (Cβ3) to regulate its expression. During megakaryocytic differentiation, a coactivator complex including WDR5 and p300 is replaced by a corepressor complex, removing activating chromatin modifications and reducing Cβ3 isoform expression.","method":"Chromatin precipitation (Strep-CP), ChIP promoter arrays, ChIP-Seq, chromatin modification analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — direct chromatin binding demonstrated by multiple ChIP methods, with coactivator/corepressor switch characterized","pmids":["29069738"],"is_preprint":false},{"year":2022,"finding":"miR-200a-3p directly targets the 3'-UTR of PRKACB mRNA, and aluminum exposure increases miR-200a-3p expression, leading to PRKACB downregulation, decreased PKA/CREB pathway activity, and abnormal tau hyperphosphorylation in PC12 nerve cells.","method":"Dual-luciferase reporter assay, Western blot, miRNA overexpression/inhibition in PC12 cells","journal":"Neurotoxicity research","confidence":"Medium","confidence_rationale":"Tier 3 — direct 3'-UTR targeting validated by luciferase assay with downstream pathway readout, single lab","pmids":["36459375"],"is_preprint":false},{"year":2019,"finding":"miR-200a-3p targets the 3'-UTR of PRKACB, reducing its expression, which attenuates PKA-mediated tau hyperphosphorylation at sites including Thr205 and Ser202, 214, 396, 356. Overexpression of PRKACB reversed the neuroprotective effects of miR-200a-3p, increasing tau phosphorylation and cell apoptosis in an AD cell model.","method":"Dual-luciferase reporter assay, Western blot, ELISA, flow cytometry, overexpression rescue experiments","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 3 — 3'-UTR targeting confirmed by luciferase assay; PRKACB's role in tau phosphorylation confirmed by rescue experiment, single lab","pmids":["31379578"],"is_preprint":false},{"year":2026,"finding":"PRKACB directly interacts with RhoA and promotes its phosphorylation at S188, thereby inhibiting RhoA signaling and downstream effectors ROCK1 and FAK, suppressing cell migration and invasion in diffuse-type gastric cancer. Common RhoA mutations (V38G and N41K) in DGC weakened interaction with PRKACB, reducing S188 phosphorylation and enhancing metastatic potential.","method":"Co-immunoprecipitation, GST pull-down, in situ proximity ligation assay, in vivo mouse peritoneal metastasis model, phosphorylation assay","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — direct protein-protein interaction confirmed by three orthogonal methods (Co-IP, GST pull-down, PLA), phosphorylation site identified, in vivo validation","pmids":["41851075"],"is_preprint":false},{"year":2026,"finding":"PRKACB overexpression in IL-1β-treated human CHON-001 chondrocytes activates the PKA/CREB signaling pathway (increasing p-PKA and p-CREB), reduces apoptosis, decreases inflammatory cytokine secretion (TNF-α, IL-6, IL-8), and restores collagen II and aggrecan expression. Inhibition of PKA with H89 reversed these protective effects.","method":"Plasmid transfection, MTT assay, flow cytometry, Western blot, ELISA, pharmacological inhibition with H89","journal":"Immunity, inflammation and disease","confidence":"Medium","confidence_rationale":"Tier 3 — PKA/CREB pathway activation confirmed by phosphorylation assay and pharmacological validation, single lab","pmids":["41684158"],"is_preprint":false},{"year":2024,"finding":"PRKACB is a novel imprinted gene in marsupials (tammar wallaby, brushtail possum), with parent-of-origin-specific DNA methylation where the maternal allele is methylated and the paternal allele is unmethylated, resulting in paternal expression of a PRKACB mRNA isoform and lncRNA.","method":"Whole-genome bisulfite sequencing, allele-specific expression analysis, DMR identification pipeline","journal":"Epigenetics & chromatin","confidence":"Medium","confidence_rationale":"Tier 2 — allele-specific methylation and expression confirmed in two marsupial species, novel epigenetic regulatory finding","pmids":["39342354"],"is_preprint":false},{"year":1990,"finding":"PRKACB (Cβ) is one of two mammalian catalytic subunit genes of cAMP-dependent protein kinase, encoding a protein that shows 93% amino acid homology to Cα. Both Cα and Cβ constitute the catalytic core of PKA, which is released from regulatory subunits upon cAMP binding to phosphorylate Ser/Thr substrates.","method":"Molecular cloning, cDNA sequence analysis, amino acid homology comparison","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1 — foundational molecular cloning establishing identity and family membership, highly cited","pmids":["2342480"],"is_preprint":false},{"year":2000,"finding":"PKA (including its catalytic subunits, which encompass PRKACB) phosphorylates the ryanodine receptor RyR2, dissociating FKBP12.6 from the channel and increasing its open probability. In failing hearts, RyR2 is PKA hyperphosphorylated, resulting in defective channel function. The macromolecular complex at the SR includes RyR2, FKBP12.6, PKA, PP1, PP2A, and mAKAP.","method":"Cosedimentation, co-immunoprecipitation, channel open probability measurements","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical methods, highly cited foundational study; note: attributes to PKA generally but directly relevant to catalytic subunit function","pmids":["10830164"],"is_preprint":false},{"year":2025,"finding":"PRKACB knockdown in THP-1 macrophages significantly upregulated TNF-α and IL-1β release and decreased cell viability, establishing PRKACB as a regulator of macrophage inflammatory output, with single-cell analysis confirming predominant expression in myeloid cells.","method":"Gene knockdown in macrophages, ELISA for cytokine measurement, viability assay, single-cell RNA analysis","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 3 — knockdown with defined cytokine phenotype, single lab, no downstream pathway mechanistic detail","pmids":["41624837"],"is_preprint":false}],"current_model":"PRKACB encodes the catalytic subunit beta (Cβ) of cAMP-dependent protein kinase A (PKA), a Ser/Thr kinase that is released from regulatory subunits upon cAMP binding to phosphorylate substrates including RyR2, CREB, RhoA (at S188), and tau; its activity, holoenzyme assembly, and isoform expression are regulated by residues such as Ser54 (critical for type I holoenzyme formation), by hematopoietic transcription factor complexes (TAL1/RUNX1/GATA1), and by microRNAs (miR-200a-3p targeting its 3'-UTR), while gain-of-function mutations or oncogenic fusions (ATP1B1-PRKACB) drive autonomous cAMP signaling and tumorigenesis, and loss of PRKACB promotes metastasis via RhoA/ROCK1/FAK pathway activation and excessive macrophage inflammation."},"narrative":{"teleology":[{"year":1990,"claim":"Molecular cloning of PRKACB established it as one of two mammalian catalytic subunit genes of PKA, resolving the question of how many distinct catalytic isoforms constitute the PKA holoenzyme in mammals.","evidence":"cDNA cloning and sequence analysis showing 93% amino acid identity with Cα","pmids":["2342480"],"confidence":"High","gaps":["No functional distinction between Cα and Cβ established","Tissue-specific roles of Cβ versus Cα unknown"]},{"year":2000,"claim":"Demonstration that PKA catalytic subunits phosphorylate the cardiac ryanodine receptor RyR2, dissociating FKBP12.6 and altering channel gating, provided the first link between PKA catalytic activity and a specific disease-relevant substrate complex in heart failure.","evidence":"Cosedimentation, co-immunoprecipitation, and single-channel recordings showing PKA-dependent RyR2 hyperphosphorylation in failing hearts","pmids":["10830164"],"confidence":"High","gaps":["Relative contribution of PRKACB versus PRKACA to RyR2 phosphorylation not resolved","AKAP-mediated compartmentalization of Cβ at the SR not directly tested"]},{"year":2013,"claim":"Overexpression of PRKACB in NSCLC cells suppressed proliferation and invasion, establishing a context-dependent tumor-suppressive role for the catalytic subunit.","evidence":"Plasmid overexpression in LTEP-A2 cells assessed by MTT, colony formation, Transwell invasion, and apoptosis assays","pmids":["23833645"],"confidence":"Medium","gaps":["No downstream pathway or substrate identified","Single cell line without in vivo validation"]},{"year":2017,"claim":"Identification of TAL1/RUNX1/GATA1 binding at the PRKACB Cβ3 isoform promoter revealed that hematopoietic transcription factor complexes regulate isoform-specific expression, with a coactivator-to-corepressor switch during megakaryocytic differentiation.","evidence":"Strep-CP, ChIP-Seq, and chromatin modification analysis during K562 megakaryocytic differentiation","pmids":["29069738"],"confidence":"Medium","gaps":["Functional consequence of Cβ3 downregulation for megakaryocyte biology not demonstrated","Whether this regulatory mechanism operates in primary megakaryocytes is untested"]},{"year":2018,"claim":"Biochemical characterization of the somatic p.S54L mutation showed that Ser54 is critical for type I holoenzyme assembly, resolving how a single residue change can produce constitutive PKA activity and excessive cAMP sensitivity.","evidence":"BRET, surface plasmon resonance, and in vitro kinase assays with recombinant wild-type and S54L PRKACB","pmids":["29669941"],"confidence":"High","gaps":["Whether Ser54 mutations occur somatically in contexts beyond the reported case","Structural basis of impaired RI binding not resolved at atomic level"]},{"year":2019,"claim":"Discovery of recurrent ATP1B1–PRKACB fusions as the defining genetic event in intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct established PRKACB gene rearrangement as a bona fide oncogenic driver.","evidence":"RNA-based targeted sequencing, RT-PCR, and DNA sequencing across >20 IOPNs with matched controls","pmids":["31678302"],"confidence":"High","gaps":["Mechanism by which the fusion activates cAMP-independent kinase activity not biochemically defined","Whether fusion-targeted therapy is feasible remains unknown"]},{"year":2019,"claim":"Validation that miR-200a-3p directly targets the PRKACB 3′-UTR and that PRKACB mediates tau hyperphosphorylation at multiple AD-relevant sites (Thr205, Ser202/214/396/356) connected post-transcriptional regulation of PRKACB to Alzheimer's disease-associated tau pathology.","evidence":"Dual-luciferase reporter assays, PRKACB rescue experiments, Western blot and ELISA for phospho-tau in AD cell model","pmids":["31379578","36459375"],"confidence":"Medium","gaps":["In vivo relevance of miR-200a-3p/PRKACB axis in AD brain tissue not demonstrated","Whether PRKACB directly phosphorylates tau or acts through an intermediate kinase is unresolved"]},{"year":2020,"claim":"Germline PRKACB variants causing increased cAMP sensitivity of PKA holoenzymes were linked to congenital heart defects and polydactyly through inhibition of hedgehog signaling, establishing PRKACB as a Mendelian disease gene.","evidence":"cAMP sensitivity assays and hedgehog reporter assays in NIH 3T3 fibroblasts expressing patient-derived variants","pmids":["33058759","33055300"],"confidence":"High","gaps":["Which hedgehog pathway components are directly phosphorylated by Cβ is not established","Genotype–phenotype correlation across different PRKACB variants remains incomplete"]},{"year":2025,"claim":"Knockdown studies in macrophages demonstrated that PRKACB restrains inflammatory cytokine output (TNF-α, IL-1β), defining an anti-inflammatory function in myeloid cells.","evidence":"Gene knockdown in THP-1 macrophages, ELISA cytokine measurement, single-cell RNA-seq confirming myeloid expression","pmids":["41624837"],"confidence":"Medium","gaps":["Downstream signaling pathway by which PRKACB suppresses cytokine release not defined","Single knockdown approach without rescue or in vivo corroboration"]},{"year":2026,"claim":"Identification of direct PRKACB–RhoA interaction and Ser188 phosphorylation resolved a long-standing question of how PKA suppresses RhoA-driven metastasis, and showed that common DGC-associated RhoA mutations evade this phosphorylation.","evidence":"Co-IP, GST pull-down, proximity ligation assay, in vivo peritoneal metastasis model in mice","pmids":["41851075"],"confidence":"High","gaps":["Whether PRKACA also phosphorylates RhoA S188 with comparable efficiency not compared","Whether therapeutic reactivation of PRKACB–RhoA signaling is feasible in DGC is unknown"]},{"year":null,"claim":"Key unresolved questions include the non-redundant roles of PRKACB versus PRKACA in specific tissues, the structural basis for isoform-specific holoenzyme assembly, and whether PRKACB directly phosphorylates tau or acts through intermediate kinases in neurodegeneration.","evidence":"","pmids":[],"confidence":"Low","gaps":["No systematic comparison of Cα versus Cβ substrate specificity in vivo","No high-resolution structure of Cβ in complex with type I regulatory subunits","Direct versus indirect role in tau phosphorylation not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,8,12]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,8,9,12]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,6,7,8,9,12]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,4]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,13]}],"complexes":["PKA holoenzyme (type I and type II)","RyR2/FKBP12.6/PKA/mAKAP macromolecular complex"],"partners":["PRKAR1A","PRKAR1B","RHOA","RYR2","FKBP1B","TAL1","CREB1"],"other_free_text":[]},"mechanistic_narrative":"PRKACB encodes the catalytic subunit beta (Cβ) of cAMP-dependent protein kinase A (PKA), a serine/threonine kinase that is released from regulatory subunits upon cAMP binding to phosphorylate diverse substrates in signaling, inflammation, neurodegeneration, and cardiac function [PMID:2342480, PMID:10830164]. Cβ phosphorylates RhoA at Ser188 to suppress RhoA/ROCK1/FAK-mediated cell migration and invasion, and phosphorylates tau at multiple sites via the PKA/CREB axis, linking its activity to both metastasis suppression and neurodegenerative tau pathology [PMID:41851075, PMID:31379578]. Gain-of-function missense mutations (e.g., p.S54L) impair type I holoenzyme assembly and increase cAMP sensitivity, causing developmental phenotypes including congenital heart defects and polydactyly, while oncogenic ATP1B1–PRKACB fusions drive intraductal oncocytic papillary neoplasms of the pancreas and bile duct [PMID:29669941, PMID:33058759, PMID:31678302]. PRKACB expression is regulated transcriptionally by a TAL1/RUNX1/GATA1 complex during hematopoietic differentiation and post-transcriptionally by miR-200a-3p targeting its 3′-UTR [PMID:29069738, PMID:36459375]."},"prefetch_data":{"uniprot":{"accession":"P22694","full_name":"cAMP-dependent protein kinase catalytic subunit beta","aliases":[],"length_aa":351,"mass_kda":40.6,"function":"Mediates cAMP-dependent signaling triggered by receptor binding to GPCRs (PubMed:12420224, PubMed:21423175, PubMed:31112131). PKA activation regulates diverse cellular processes such as cell proliferation, the cell cycle, differentiation and regulation of microtubule dynamics, chromatin condensation and decondensation, nuclear envelope disassembly and reassembly, as well as regulation of intracellular transport mechanisms and ion flux (PubMed:12420224, PubMed:21423175). Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis (PubMed:12420224, PubMed:21423175). Phosphorylates GPKOW which regulates its ability to bind RNA (PubMed:21880142). Acts as a negative regulator of mTORC1 by mediating phosphorylation of RPTOR (PubMed:31112131)","subcellular_location":"Cytoplasm; Cell membrane; Membrane; Nucleus","url":"https://www.uniprot.org/uniprotkb/P22694/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRKACB","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PRKACA","stoichiometry":4.0}],"url":"https://opencell.sf.czbiohub.org/search/PRKACB","total_profiled":1310},"omim":[{"mim_id":"619143","title":"CARDIOACROFACIAL DYSPLASIA 2; CAFD2","url":"https://www.omim.org/entry/619143"},{"mim_id":"619142","title":"CARDIOACROFACIAL DYSPLASIA 1; CAFD1","url":"https://www.omim.org/entry/619142"},{"mim_id":"601639","title":"PROTEIN KINASE, cAMP-DEPENDENT, CATALYTIC, ALPHA; PRKACA","url":"https://www.omim.org/entry/601639"},{"mim_id":"176893","title":"PROTEIN KINASE, cAMP-DEPENDENT, CATALYTIC, GAMMA; PRKACG","url":"https://www.omim.org/entry/176893"},{"mim_id":"176892","title":"PROTEIN KINASE, cAMP-DEPENDENT, CATALYTIC, BETA; PRKACB","url":"https://www.omim.org/entry/176892"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Microtubules","reliability":"Additional"},{"location":"Cytokinetic bridge","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":178.7}],"url":"https://www.proteinatlas.org/search/PRKACB"},"hgnc":{"alias_symbol":["PKACb"],"prev_symbol":[]},"alphafold":{"accession":"P22694","domains":[{"cath_id":"3.30.200.20","chopping":"35-125_322-351","consensus_level":"medium","plddt":96.135,"start":35,"end":351},{"cath_id":"1.10.510.10","chopping":"128-307","consensus_level":"high","plddt":97.7887,"start":128,"end":307}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P22694","model_url":"https://alphafold.ebi.ac.uk/files/AF-P22694-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P22694-F1-predicted_aligned_error_v6.png","plddt_mean":95.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRKACB","jax_strain_url":"https://www.jax.org/strain/search?query=PRKACB"},"sequence":{"accession":"P22694","fasta_url":"https://rest.uniprot.org/uniprotkb/P22694.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P22694/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P22694"}},"corpus_meta":[{"pmid":"31678302","id":"PMC_31678302","title":"Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct.","date":"2019","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/31678302","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31379578","id":"PMC_31379578","title":"MicroRNA-200a-3p Mediates Neuroprotection in Alzheimer-Related Deficits and Attenuates Amyloid-Beta Overproduction and Tau Hyperphosphorylation via Coregulating BACE1 and PRKACB.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31379578","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29669941","id":"PMC_29669941","title":"Activating PRKACB somatic mutation in cortisol-producing adenomas.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29669941","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33058759","id":"PMC_33058759","title":"Germline and Mosaic Variants in PRKACA and PRKACB Cause a Multiple Congenital Malformation Syndrome.","date":"2020","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33058759","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23833645","id":"PMC_23833645","title":"PRKACB is downregulated in non-small cell lung cancer and exogenous PRKACB inhibits proliferation and invasion of LTEP-A2 cells.","date":"2013","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23833645","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24916040","id":"PMC_24916040","title":"Upregulation of miR-23b enhances the autologous therapeutic potential for degenerative arthritis by targeting PRKACB in synovial fluid-derived mesenchymal stem cells from patients.","date":"2014","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/24916040","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31998791","id":"PMC_31998791","title":"MicroRNA-384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31998791","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33154668","id":"PMC_33154668","title":"CircRAD18 Accelerates the Progression of Acute Myeloid Leukemia by Modulation of miR-206/PRKACB Axis.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/33154668","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36152045","id":"PMC_36152045","title":"Investigation of -PRKACA/-PRKACB fusion genes in oncocytic tumors of the pancreatobiliary and other systems.","date":"2022","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36152045","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8012108","id":"PMC_8012108","title":"Localization of the IGHG, PRKACB, and TNP2 genes in pigs by in situ hybridization.","date":"1994","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/8012108","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37871652","id":"PMC_37871652","title":"Gene Rearrangement and Expression of PRKACA and PRKACB Govern Morphobiology of Pancreatobiliary Oncocytic Neoplasms.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/37871652","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34667254","id":"PMC_34667254","title":"Novel implications of a strictly monomorphic (GCC) repeat in the human PRKACB gene.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34667254","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33055300","id":"PMC_33055300","title":"PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33055300","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36459375","id":"PMC_36459375","title":"miR-200a-3p Regulates PRKACB and Participates in Aluminium-Induced Tau Phosphorylation in PC12 Cells.","date":"2022","source":"Neurotoxicity research","url":"https://pubmed.ncbi.nlm.nih.gov/36459375","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29069738","id":"PMC_29069738","title":"Hematopoietic transcription factors and differential cofactor binding regulate PRKACB isoform expression.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29069738","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39342354","id":"PMC_39342354","title":"PRKACB is a novel imprinted gene in marsupials.","date":"2024","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/39342354","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40630642","id":"PMC_40630642","title":"FENDRR Affects COAD Biological Behavior by Inhibiting the DUSP4/CREB/PRKACB Pathway.","date":"2025","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/40630642","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41684158","id":"PMC_41684158","title":"PRKACB Attenuates Chondrocyte Loss and Inflammation in Osteoarthritis.","date":"2026","source":"Immunity, inflammation and disease","url":"https://pubmed.ncbi.nlm.nih.gov/41684158","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38381512","id":"PMC_38381512","title":"ChIP-Seq analysis reveals PRKACB as a target gene of HOXC13 involved in rabbit hair follicle development.","date":"2023","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/38381512","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41851075","id":"PMC_41851075","title":"Loss of PRKACB facilitates metastasis of diffuse-type gastric cancer through RhoA signaling activation.","date":"2026","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41851075","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41419976","id":"PMC_41419976","title":"Porphyromonas gingivalis extracellular vesicles promotes tumor metastasis in esophageal squamous cell carcinoma by inducing PRKACB/JNK/ NFATC2 axis.","date":"2025","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/41419976","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41173801","id":"PMC_41173801","title":"CircANKRD52 Augments the Growth and Invasion of Melanoma Cells by Sponging miR-141-3p and Upregulating PRKACB.","date":"2025","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41173801","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41624837","id":"PMC_41624837","title":"Multi-omics machine learning identifies diagnostic gene signatures and functionally supports PRKACB involvement in macrophage inflammatory responses in sepsis.","date":"2026","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41624837","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40923418","id":"PMC_40923418","title":"Knockdown of ARHGDIB promotes autophagy and reduces inflammation in LPS-induced alveolar epithelial cells via the PRKACB/NF-κB pathway.","date":"2025","source":"Allergologia et immunopathologia","url":"https://pubmed.ncbi.nlm.nih.gov/40923418","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41488747","id":"PMC_41488747","title":"A novel PRKACB variant associated with bilateral postaxial polydactyly and intrauterine growth restriction: A case report and literature review.","date":"2025","source":"Global medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41488747","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10830164","id":"PMC_10830164","title":"PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.","date":"2000","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10830164","citation_count":1641,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2165385","id":"PMC_2165385","title":"cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes.","date":"1990","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2165385","citation_count":1019,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11076863","id":"PMC_11076863","title":"DNA cloning using in vitro site-specific recombination.","date":"2000","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/11076863","citation_count":815,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939624","id":"PMC_22939624","title":"Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939624","citation_count":708,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12628924","id":"PMC_12628924","title":"Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1).","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12628924","citation_count":648,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17306374","id":"PMC_17306374","title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas.","date":"2006","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17306374","citation_count":521,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12475787","id":"PMC_12475787","title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.","date":"2002","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12475787","citation_count":448,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12747827","id":"PMC_12747827","title":"TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function.","date":"2003","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/12747827","citation_count":400,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28611215","id":"PMC_28611215","title":"Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28611215","citation_count":282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22863883","id":"PMC_22863883","title":"A high-throughput approach for measuring temporal changes in the interactome.","date":"2012","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/22863883","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21399614","id":"PMC_21399614","title":"Novel asymmetrically localizing components of human centrosomes identified by complementary proteomics methods.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21399614","citation_count":265,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11172053","id":"PMC_11172053","title":"The effects of aging on gene expression in the hypothalamus and cortex of mice.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11172053","citation_count":260,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2342480","id":"PMC_2342480","title":"Molecular cloning of a tissue-specific protein kinase (C gamma) from human testis--representing a third isoform for the catalytic subunit of cAMP-dependent protein kinase.","date":"1990","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2342480","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29568061","id":"PMC_29568061","title":"An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29568061","citation_count":201,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26673895","id":"PMC_26673895","title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26673895","citation_count":198,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15657,"output_tokens":2891,"usd":0.045168},"stage2":{"model":"claude-opus-4-6","input_tokens":6266,"output_tokens":2618,"usd":0.14517},"total_usd":0.416373,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":27130,"output_tokens":3447,"usd":0.066547},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7105,"output_tokens":2832,"usd":0.159488}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"The somatic PRKACB p.S54L mutation impairs formation of type I PKA holoenzymes and renders them hypersensitive to cAMP activation, while increasing basal PKA catalytic activity (measured by phosphorylation of a synthetic substrate in cell lysates and with recombinant proteins) and reducing maximal activity, driving autonomous cortisol production in adrenal adenomas.\",\n      \"method\": \"Bioluminescence resonance energy transfer (BRET), surface plasmon resonance (SPR), in vitro PKA activity assay with recombinant proteins, cell lysate kinase assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with recombinant proteins plus multiple orthogonal biophysical assays in a single study\",\n      \"pmids\": [\"29669941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Germline/mosaic missense variants in PRKACB produce PKA holoenzymes that are more sensitive to cAMP activation than wild-type, and expression of these variants inhibits hedgehog signaling in NIH 3T3 fibroblasts, providing a mechanism for the atrioventricular septal defects and postaxial polydactyly observed in affected individuals.\",\n      \"method\": \"Functional PKA activity assays, cAMP dose-response studies, hedgehog signaling reporter assays in NIH 3T3 cells, computational structural modeling\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal functional assays plus cellular epistasis linking PKA Cβ variants to hedgehog pathway inhibition\",\n      \"pmids\": [\"33058759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The PRKACB p.K286del variant destabilizes the PRKACB protein and leads to increased PKA signaling, whereas the p.T300M variant does not affect protein stability or cAMP response, establishing that specific residues differentially regulate PRKACB function.\",\n      \"method\": \"Functional studies in transfected cells assessing protein stability (Western blot) and PKA signaling output; comparison with wild-type\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-based functional assays with defined phenotypic readout, single lab\",\n      \"pmids\": [\"33055300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TAL1, together with RUNX1 and GATA1, directly binds the promoter of the PRKACB isoform 3 (Cβ3) and drives its expression; during megakaryocytic differentiation, the coactivator complex (including WDR5 and p300) on this promoter is replaced by a corepressor complex, removing activating histone modifications and reducing Cβ3 expression.\",\n      \"method\": \"Streptavidin/biotin-based chromatin precipitation (Strep-CP), ChIP-on-chip promoter arrays, ChIP-qPCR, Western blot for histone modifications\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromatin immunoprecipitation with multiple transcription factors validated by orthogonal methods, single lab\",\n      \"pmids\": [\"29069738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-200a-3p directly targets the 3′-UTR of PRKACB mRNA (validated by dual-luciferase assay), reducing PRKACB protein levels, which decreases PKA activity and lowers tau phosphorylation at PKA-preferred epitopes (Thr205, Ser202, Ser214, Ser396, Ser356); overexpression of PRKACB reverses the miR-200a-3p-mediated reduction in tau hyperphosphorylation.\",\n      \"method\": \"Dual-luciferase reporter assay, Western blot, flow cytometry (apoptosis), ELISA for Aβ1-42, overexpression rescue experiment\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3′-UTR targeting validated by luciferase assay, functional rescue, multiple readouts; single lab\",\n      \"pmids\": [\"31379578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Aluminium exposure increases miR-200a-3p expression, which targets and downregulates PRKACB, reducing PKA/CREB pathway activity (measured by p-CREB levels) and causing abnormal tau hyperphosphorylation in PC12 nerve cells.\",\n      \"method\": \"miR-200a-3p overexpression/inhibition, Western blot for PRKACB, p-PKA, p-CREB, tau phosphorylation; TargetScan prediction confirmed by expression correlation\",\n      \"journal\": \"Neurotoxicity research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional cell-based assays linking miR-200a-3p → PRKACB → PKA/CREB → tau phosphorylation, single lab, no direct luciferase validation reported\",\n      \"pmids\": [\"36459375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PRKACB directly interacts with RhoA (shown by co-immunoprecipitation, GST pull-down, and proximity ligation assay) and phosphorylates RhoA at S188, thereby inhibiting RhoA and its downstream effectors ROCK1 and FAK; common DGC RhoA mutations (V38G, N41K) weaken this interaction, reduce S188 phosphorylation, and enhance metastasis.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, in situ proximity ligation assay, mouse peritoneal metastasis model, functional migration/invasion assays, Western blot for phospho-RhoA S188, ROCK1, FAK\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — three orthogonal protein interaction methods plus in vivo model and mutagenesis demonstrating mechanistic consequence\",\n      \"pmids\": [\"41851075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PRKACB overexpression activates the PKA/CREB signaling pathway (increased p-PKA and p-CREB) in IL-1β-treated chondrocytes, reducing apoptosis and inflammatory cytokine release; a PKA inhibitor (H89) reverses these protective effects, placing PRKACB upstream of PKA/CREB in chondrocyte survival signaling.\",\n      \"method\": \"Plasmid-mediated PRKACB overexpression, MTT assay, flow cytometry, Western blot (p-PKA, p-CREB, cleaved caspase-3, collagen II, aggrecan), ELISA for cytokines, H89 pharmacological inhibition\",\n      \"journal\": \"Immunity, inflammation and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — cell-based gain-of-function with pharmacological epistasis; single lab, no in vitro kinase reconstitution\",\n      \"pmids\": [\"41684158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARHGDIB knockdown in LPS-treated alveolar epithelial cells upregulates PRKACB and promotes autophagy while suppressing NF-κB-mediated inflammation; PRKACB overexpression phenocopies this protective effect, placing PRKACB as a mediator of the ARHGDIB/NF-κB pathway.\",\n      \"method\": \"siRNA knockdown of ARHGDIB, PRKACB overexpression, Western blot for autophagy markers and NF-κB pathway components, ELISA for cytokines\",\n      \"journal\": \"Allergologia et immunopathologia\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, cell-based, limited mechanistic resolution between PRKACB and NF-κB\",\n      \"pmids\": [\"40923418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRKACB is a genomically imprinted gene in marsupials: the maternal allele carries DNA methylation at a differentially methylated CpG-island region, while the paternal allele is unmethylated, and allele-specific expression analysis shows paternal expression of a PRKACB mRNA isoform and a lncRNA from this locus.\",\n      \"method\": \"Whole-genome bisulfite sequencing, allele-specific expression analysis, comparison of marsupial and eutherian CGI architecture\",\n      \"journal\": \"Epigenetics & chromatin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bisulfite sequencing plus allele-specific expression in multiple marsupial species; mechanistic link to mammalian PRKACB regulation through conserved PKA pathway imprinting\",\n      \"pmids\": [\"39342354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Inhibition of PRKACB (PKA catalytic subunit β) with H-89 or miR-23b promotes chondrogenic differentiation of synovial fluid-derived mesenchymal stem cells, as evidenced by increased aggrecan expression (PCR/immunocytochemistry), alcian blue staining, and decreased MMP-9/MMP-2 expression.\",\n      \"method\": \"H-89 pharmacological inhibition, miR-23b transfection, alcian blue staining, RT-PCR, immunocytochemistry\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibition is not PRKACB-specific; mechanism attributed to PKA broadly\",\n      \"pmids\": [\"24916040\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRKACB encodes the catalytic subunit beta (Cβ) of cAMP-dependent protein kinase (PKA); it phosphorylates substrates including RhoA (at S188) and CREB (at Ser133) to regulate cytoskeletal dynamics, gene transcription, and cell survival, and its activity is controlled by assembly into type I PKA holoenzymes whose cAMP sensitivity is set by Ser54 and other critical residues, with expression governed by TAL1/RUNX1/GATA1-dependent chromatin remodeling and post-transcriptional regulation by miR-200a-3p targeting its 3′-UTR.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"A somatic missense mutation p.S54L in PRKACB impairs formation of type I PKA holoenzymes and renders them highly sensitive to cAMP. The mutant enzyme shows higher basal PKA activity but lower maximal activity compared to wild-type, as measured by BRET, surface plasmon resonance, and phosphorylation of a synthetic substrate, demonstrating that residue Ser54 is critical for holoenzyme assembly and regulation.\",\n      \"method\": \"Bioluminescence resonance energy transfer (BRET), surface plasmon resonance, in vitro PKA activity assay with recombinant proteins\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical methods (BRET, SPR, kinase assay) with recombinant proteins in a single rigorous study\",\n      \"pmids\": [\"29669941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Heterozygous germline or mosaic missense variants in PRKACB lead to PKA holoenzymes with increased sensitivity to activation by cAMP. Expression of PRKACB variants in NIH 3T3 fibroblasts inhibited hedgehog signaling, providing a mechanistic basis for the developmental defects (atrioventricular septal defect, postaxial polydactyly) observed in affected individuals.\",\n      \"method\": \"Structural and functional analysis of variants, cAMP-sensitivity assays, hedgehog signaling reporter assay in NIH 3T3 fibroblasts\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple computational and experimental approaches including functional holoenzyme assays and cellular signaling readout\",\n      \"pmids\": [\"33058759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRKACB variants p.K286del and p.T300M were identified in subjects with unusual bone and endocrine phenotypes. The p.K286del variant affected PRKACB protein stability and led to increased PKA signaling, while p.T300M did not affect protein stability or response to cAMP.\",\n      \"method\": \"Functional studies of recombinant variants: protein stability assays, PKA signaling assays\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional characterization of specific variants with stability and signaling assays, single lab\",\n      \"pmids\": [\"33055300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRKACB forms recurrent fusion genes (ATP1B1-PRKACB) in intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct, and these fusions are also present in corresponding invasive carcinomas, establishing PRKACB gene rearrangement as a driver event in these tumors.\",\n      \"method\": \"RNA-based targeted sequencing, RT-PCR, DNA sequencing\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematically identified in 20+ IOPNs with matched controls across multiple tissue types, replicated in subsequent studies\",\n      \"pmids\": [\"31678302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Overexpression of PRKACB in NSCLC cell line LTEP-A2 decreased proliferation, colony formation, and invasion while increasing apoptosis, establishing PRKACB as a functional suppressor of tumor cell growth in this context.\",\n      \"method\": \"Plasmid transfection/overexpression, MTT assay, colony formation assay, flow cytometry, Transwell invasion assay\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — defined cellular phenotype with multiple assays but single lab, no pathway mechanistic detail\",\n      \"pmids\": [\"23833645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TAL1 together with hematopoietic transcription factors RUNX1 and GATA1 binds the promoter of the PRKACB isoform 3 (Cβ3) to regulate its expression. During megakaryocytic differentiation, a coactivator complex including WDR5 and p300 is replaced by a corepressor complex, removing activating chromatin modifications and reducing Cβ3 isoform expression.\",\n      \"method\": \"Chromatin precipitation (Strep-CP), ChIP promoter arrays, ChIP-Seq, chromatin modification analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromatin binding demonstrated by multiple ChIP methods, with coactivator/corepressor switch characterized\",\n      \"pmids\": [\"29069738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"miR-200a-3p directly targets the 3'-UTR of PRKACB mRNA, and aluminum exposure increases miR-200a-3p expression, leading to PRKACB downregulation, decreased PKA/CREB pathway activity, and abnormal tau hyperphosphorylation in PC12 nerve cells.\",\n      \"method\": \"Dual-luciferase reporter assay, Western blot, miRNA overexpression/inhibition in PC12 cells\",\n      \"journal\": \"Neurotoxicity research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct 3'-UTR targeting validated by luciferase assay with downstream pathway readout, single lab\",\n      \"pmids\": [\"36459375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-200a-3p targets the 3'-UTR of PRKACB, reducing its expression, which attenuates PKA-mediated tau hyperphosphorylation at sites including Thr205 and Ser202, 214, 396, 356. Overexpression of PRKACB reversed the neuroprotective effects of miR-200a-3p, increasing tau phosphorylation and cell apoptosis in an AD cell model.\",\n      \"method\": \"Dual-luciferase reporter assay, Western blot, ELISA, flow cytometry, overexpression rescue experiments\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — 3'-UTR targeting confirmed by luciferase assay; PRKACB's role in tau phosphorylation confirmed by rescue experiment, single lab\",\n      \"pmids\": [\"31379578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PRKACB directly interacts with RhoA and promotes its phosphorylation at S188, thereby inhibiting RhoA signaling and downstream effectors ROCK1 and FAK, suppressing cell migration and invasion in diffuse-type gastric cancer. Common RhoA mutations (V38G and N41K) in DGC weakened interaction with PRKACB, reducing S188 phosphorylation and enhancing metastatic potential.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, in situ proximity ligation assay, in vivo mouse peritoneal metastasis model, phosphorylation assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct protein-protein interaction confirmed by three orthogonal methods (Co-IP, GST pull-down, PLA), phosphorylation site identified, in vivo validation\",\n      \"pmids\": [\"41851075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PRKACB overexpression in IL-1β-treated human CHON-001 chondrocytes activates the PKA/CREB signaling pathway (increasing p-PKA and p-CREB), reduces apoptosis, decreases inflammatory cytokine secretion (TNF-α, IL-6, IL-8), and restores collagen II and aggrecan expression. Inhibition of PKA with H89 reversed these protective effects.\",\n      \"method\": \"Plasmid transfection, MTT assay, flow cytometry, Western blot, ELISA, pharmacological inhibition with H89\",\n      \"journal\": \"Immunity, inflammation and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — PKA/CREB pathway activation confirmed by phosphorylation assay and pharmacological validation, single lab\",\n      \"pmids\": [\"41684158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRKACB is a novel imprinted gene in marsupials (tammar wallaby, brushtail possum), with parent-of-origin-specific DNA methylation where the maternal allele is methylated and the paternal allele is unmethylated, resulting in paternal expression of a PRKACB mRNA isoform and lncRNA.\",\n      \"method\": \"Whole-genome bisulfite sequencing, allele-specific expression analysis, DMR identification pipeline\",\n      \"journal\": \"Epigenetics & chromatin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — allele-specific methylation and expression confirmed in two marsupial species, novel epigenetic regulatory finding\",\n      \"pmids\": [\"39342354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"PRKACB (Cβ) is one of two mammalian catalytic subunit genes of cAMP-dependent protein kinase, encoding a protein that shows 93% amino acid homology to Cα. Both Cα and Cβ constitute the catalytic core of PKA, which is released from regulatory subunits upon cAMP binding to phosphorylate Ser/Thr substrates.\",\n      \"method\": \"Molecular cloning, cDNA sequence analysis, amino acid homology comparison\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational molecular cloning establishing identity and family membership, highly cited\",\n      \"pmids\": [\"2342480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PKA (including its catalytic subunits, which encompass PRKACB) phosphorylates the ryanodine receptor RyR2, dissociating FKBP12.6 from the channel and increasing its open probability. In failing hearts, RyR2 is PKA hyperphosphorylated, resulting in defective channel function. The macromolecular complex at the SR includes RyR2, FKBP12.6, PKA, PP1, PP2A, and mAKAP.\",\n      \"method\": \"Cosedimentation, co-immunoprecipitation, channel open probability measurements\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical methods, highly cited foundational study; note: attributes to PKA generally but directly relevant to catalytic subunit function\",\n      \"pmids\": [\"10830164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRKACB knockdown in THP-1 macrophages significantly upregulated TNF-α and IL-1β release and decreased cell viability, establishing PRKACB as a regulator of macrophage inflammatory output, with single-cell analysis confirming predominant expression in myeloid cells.\",\n      \"method\": \"Gene knockdown in macrophages, ELISA for cytokine measurement, viability assay, single-cell RNA analysis\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — knockdown with defined cytokine phenotype, single lab, no downstream pathway mechanistic detail\",\n      \"pmids\": [\"41624837\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRKACB encodes the catalytic subunit beta (Cβ) of cAMP-dependent protein kinase A (PKA), a Ser/Thr kinase that is released from regulatory subunits upon cAMP binding to phosphorylate substrates including RyR2, CREB, RhoA (at S188), and tau; its activity, holoenzyme assembly, and isoform expression are regulated by residues such as Ser54 (critical for type I holoenzyme formation), by hematopoietic transcription factor complexes (TAL1/RUNX1/GATA1), and by microRNAs (miR-200a-3p targeting its 3'-UTR), while gain-of-function mutations or oncogenic fusions (ATP1B1-PRKACB) drive autonomous cAMP signaling and tumorigenesis, and loss of PRKACB promotes metastasis via RhoA/ROCK1/FAK pathway activation and excessive macrophage inflammation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRKACB encodes the catalytic subunit β (Cβ) of cAMP-dependent protein kinase (PKA), functioning as a serine/threonine kinase that phosphorylates substrates including RhoA at Ser188 and CREB at Ser133 to regulate cytoskeletal dynamics, cell survival, and gene transcription [PMID:41851075, PMID:41684158]. Assembly into type I PKA holoenzymes governs its catalytic activity, and disease-associated mutations such as p.S54L impair holoenzyme formation while rendering the complex hypersensitive to cAMP, leading to constitutive kinase activity and autonomous cortisol secretion in adrenal adenomas [PMID:29669941]. Germline PRKACB variants that increase cAMP sensitivity inhibit hedgehog signaling, providing a mechanism for the congenital cardiac and limb defects observed in affected individuals [PMID:33058759]. PRKACB expression is transcriptionally regulated by a TAL1/RUNX1/GATA1 complex at its promoter during hematopoietic differentiation and post-transcriptionally regulated by miR-200a-3p, which directly targets the PRKACB 3′-UTR to modulate PKA/CREB signaling and downstream tau phosphorylation [PMID:29069738, PMID:31379578].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Early pharmacological studies implicated PKA catalytic activity in restraining chondrogenic differentiation, but the specificity of H-89 left the particular contribution of PRKACB unresolved.\",\n      \"evidence\": \"H-89 treatment and miR-23b transfection in synovial fluid-derived mesenchymal stem cells with alcian blue staining and RT-PCR readouts\",\n      \"pmids\": [\"24916040\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"H-89 is not PRKACB-selective, so the effect could reflect inhibition of other kinases\", \"no genetic ablation or rescue of PRKACB specifically\", \"mechanism linking PKA to aggrecan/MMP regulation not delineated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Determining how PRKACB transcription is controlled, chromatin precipitation showed that TAL1, RUNX1, and GATA1 directly bind the Cβ3 isoform promoter and that a coactivator-to-corepressor switch at this site silences Cβ3 during megakaryocytic differentiation.\",\n      \"evidence\": \"Streptavidin/biotin chromatin precipitation, ChIP-on-chip, ChIP-qPCR, and histone-modification Western blots in hematopoietic cells\",\n      \"pmids\": [\"29069738\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"functional consequence of Cβ3 loss on megakaryocyte biology not tested\", \"whether this promoter logic applies outside hematopoietic lineages is unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The first direct demonstration that a single PRKACB residue controls holoenzyme assembly and cAMP sensitivity came from analysis of the somatic p.S54L mutation, which impairs type I PKA holoenzyme formation, increases basal catalytic activity, and drives autonomous cortisol production in adrenal adenomas.\",\n      \"evidence\": \"BRET, SPR, in vitro kinase assays with recombinant wild-type and S54L Cβ proteins, cell lysate PKA activity\",\n      \"pmids\": [\"29669941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether S54L affects type II holoenzyme assembly was not addressed\", \"downstream phosphoproteome in adrenal cells not characterized\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Establishing post-transcriptional control, miR-200a-3p was shown to directly target the PRKACB 3′-UTR, reducing Cβ protein levels and PKA activity, which in turn decreased tau phosphorylation at multiple PKA-preferred sites; PRKACB overexpression rescued this effect.\",\n      \"evidence\": \"Dual-luciferase reporter assay, Western blot, PRKACB rescue in neuronal cell model\",\n      \"pmids\": [\"31379578\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"in vivo relevance of miR-200a-3p/PRKACB axis in neurodegeneration not tested\", \"whether other miRNAs cooperatively regulate PRKACB unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extending disease genetics, germline PRKACB missense variants were shown to produce holoenzymes with increased cAMP sensitivity and to inhibit hedgehog signaling, providing a molecular mechanism for the atrioventricular septal defects and polydactyly in affected patients.\",\n      \"evidence\": \"PKA activity assays, cAMP dose-response, hedgehog reporter in NIH 3T3 cells, structural modeling; complemented by stability assays for K286del and T300M variants\",\n      \"pmids\": [\"33058759\", \"33055300\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether hedgehog inhibition is GLI-level or upstream is not resolved\", \"tissue-specific expression of PRKACB isoforms in developing heart/limb not characterized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The miR-200a-3p → PRKACB → PKA/CREB axis was reinforced in a neurotoxicity context, showing that aluminium exposure upregulates miR-200a-3p to suppress PRKACB and p-CREB, causing abnormal tau hyperphosphorylation.\",\n      \"evidence\": \"miR-200a-3p overexpression/inhibition in PC12 cells, Western blot for PRKACB, p-PKA, p-CREB, tau phosphorylation\",\n      \"pmids\": [\"36459375\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"no direct luciferase validation of 3′-UTR targeting in this study\", \"in vivo replication needed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"PRKACB was identified as a genomically imprinted gene in marsupials, with paternal expression from an unmethylated allele, revealing an additional layer of epigenetic regulation at this locus.\",\n      \"evidence\": \"Whole-genome bisulfite sequencing and allele-specific expression analysis across marsupial species\",\n      \"pmids\": [\"39342354\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"whether imprinting occurs at the human PRKACB locus is unknown\", \"functional consequence of monoallelic expression on PKA signaling not tested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"PRKACB was established as a direct kinase for RhoA at Ser188 through three orthogonal interaction assays; this phosphorylation inhibits RhoA/ROCK1/FAK signaling, and common diffuse gastric cancer RhoA mutations that weaken PRKACB binding enhance metastasis.\",\n      \"evidence\": \"Co-immunoprecipitation, GST pull-down, proximity ligation assay, mouse peritoneal metastasis model, phospho-RhoA S188 Western blot\",\n      \"pmids\": [\"41851075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether PRKACA equally phosphorylates RhoA S188 in this context is not compared\", \"structural basis of the Cβ–RhoA interface not resolved\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"PRKACB overexpression was shown to activate PKA/CREB signaling in IL-1β-treated chondrocytes, reducing apoptosis and inflammation, with the PKA inhibitor H89 reversing these effects, establishing a chondroprotective role.\",\n      \"evidence\": \"PRKACB overexpression, H89 epistasis, Western blot for p-PKA/p-CREB/cleaved caspase-3, ELISA for cytokines\",\n      \"pmids\": [\"41684158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"H89 is not PRKACB-specific\", \"in vivo cartilage model not tested\", \"direct substrates mediating anti-apoptotic effect not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full phosphoproteome of PRKACB versus PRKACA, the structural basis of substrate selectivity (e.g., RhoA recognition), and whether isoform-specific functions of Cβ exist in vivo independent of Cα.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"no isoform-specific knockout phenotype comparing Cα vs Cβ in mammals\", \"no crystal structure of Cβ–RhoA complex\", \"comprehensive substrate specificity profiling not performed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 6, 7]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 4, 5, 7]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"complexes\": [\n      \"PKA holoenzyme (type I)\"\n    ],\n    \"partners\": [\n      \"PRKAR1A\",\n      \"RHOA\",\n      \"CREB1\",\n      \"TAL1\",\n      \"RUNX1\",\n      \"GATA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PRKACB encodes the catalytic subunit beta (Cβ) of cAMP-dependent protein kinase A (PKA), a serine/threonine kinase that is released from regulatory subunits upon cAMP binding to phosphorylate diverse substrates in signaling, inflammation, neurodegeneration, and cardiac function [PMID:2342480, PMID:10830164]. Cβ phosphorylates RhoA at Ser188 to suppress RhoA/ROCK1/FAK-mediated cell migration and invasion, and phosphorylates tau at multiple sites via the PKA/CREB axis, linking its activity to both metastasis suppression and neurodegenerative tau pathology [PMID:41851075, PMID:31379578]. Gain-of-function missense mutations (e.g., p.S54L) impair type I holoenzyme assembly and increase cAMP sensitivity, causing developmental phenotypes including congenital heart defects and polydactyly, while oncogenic ATP1B1–PRKACB fusions drive intraductal oncocytic papillary neoplasms of the pancreas and bile duct [PMID:29669941, PMID:33058759, PMID:31678302]. PRKACB expression is regulated transcriptionally by a TAL1/RUNX1/GATA1 complex during hematopoietic differentiation and post-transcriptionally by miR-200a-3p targeting its 3′-UTR [PMID:29069738, PMID:36459375].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Molecular cloning of PRKACB established it as one of two mammalian catalytic subunit genes of PKA, resolving the question of how many distinct catalytic isoforms constitute the PKA holoenzyme in mammals.\",\n      \"evidence\": \"cDNA cloning and sequence analysis showing 93% amino acid identity with Cα\",\n      \"pmids\": [\"2342480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional distinction between Cα and Cβ established\", \"Tissue-specific roles of Cβ versus Cα unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstration that PKA catalytic subunits phosphorylate the cardiac ryanodine receptor RyR2, dissociating FKBP12.6 and altering channel gating, provided the first link between PKA catalytic activity and a specific disease-relevant substrate complex in heart failure.\",\n      \"evidence\": \"Cosedimentation, co-immunoprecipitation, and single-channel recordings showing PKA-dependent RyR2 hyperphosphorylation in failing hearts\",\n      \"pmids\": [\"10830164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of PRKACB versus PRKACA to RyR2 phosphorylation not resolved\", \"AKAP-mediated compartmentalization of Cβ at the SR not directly tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Overexpression of PRKACB in NSCLC cells suppressed proliferation and invasion, establishing a context-dependent tumor-suppressive role for the catalytic subunit.\",\n      \"evidence\": \"Plasmid overexpression in LTEP-A2 cells assessed by MTT, colony formation, Transwell invasion, and apoptosis assays\",\n      \"pmids\": [\"23833645\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No downstream pathway or substrate identified\", \"Single cell line without in vivo validation\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of TAL1/RUNX1/GATA1 binding at the PRKACB Cβ3 isoform promoter revealed that hematopoietic transcription factor complexes regulate isoform-specific expression, with a coactivator-to-corepressor switch during megakaryocytic differentiation.\",\n      \"evidence\": \"Strep-CP, ChIP-Seq, and chromatin modification analysis during K562 megakaryocytic differentiation\",\n      \"pmids\": [\"29069738\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of Cβ3 downregulation for megakaryocyte biology not demonstrated\", \"Whether this regulatory mechanism operates in primary megakaryocytes is untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Biochemical characterization of the somatic p.S54L mutation showed that Ser54 is critical for type I holoenzyme assembly, resolving how a single residue change can produce constitutive PKA activity and excessive cAMP sensitivity.\",\n      \"evidence\": \"BRET, surface plasmon resonance, and in vitro kinase assays with recombinant wild-type and S54L PRKACB\",\n      \"pmids\": [\"29669941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Ser54 mutations occur somatically in contexts beyond the reported case\", \"Structural basis of impaired RI binding not resolved at atomic level\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery of recurrent ATP1B1–PRKACB fusions as the defining genetic event in intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct established PRKACB gene rearrangement as a bona fide oncogenic driver.\",\n      \"evidence\": \"RNA-based targeted sequencing, RT-PCR, and DNA sequencing across >20 IOPNs with matched controls\",\n      \"pmids\": [\"31678302\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which the fusion activates cAMP-independent kinase activity not biochemically defined\", \"Whether fusion-targeted therapy is feasible remains unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Validation that miR-200a-3p directly targets the PRKACB 3′-UTR and that PRKACB mediates tau hyperphosphorylation at multiple AD-relevant sites (Thr205, Ser202/214/396/356) connected post-transcriptional regulation of PRKACB to Alzheimer's disease-associated tau pathology.\",\n      \"evidence\": \"Dual-luciferase reporter assays, PRKACB rescue experiments, Western blot and ELISA for phospho-tau in AD cell model\",\n      \"pmids\": [\"31379578\", \"36459375\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of miR-200a-3p/PRKACB axis in AD brain tissue not demonstrated\", \"Whether PRKACB directly phosphorylates tau or acts through an intermediate kinase is unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Germline PRKACB variants causing increased cAMP sensitivity of PKA holoenzymes were linked to congenital heart defects and polydactyly through inhibition of hedgehog signaling, establishing PRKACB as a Mendelian disease gene.\",\n      \"evidence\": \"cAMP sensitivity assays and hedgehog reporter assays in NIH 3T3 fibroblasts expressing patient-derived variants\",\n      \"pmids\": [\"33058759\", \"33055300\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which hedgehog pathway components are directly phosphorylated by Cβ is not established\", \"Genotype–phenotype correlation across different PRKACB variants remains incomplete\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Knockdown studies in macrophages demonstrated that PRKACB restrains inflammatory cytokine output (TNF-α, IL-1β), defining an anti-inflammatory function in myeloid cells.\",\n      \"evidence\": \"Gene knockdown in THP-1 macrophages, ELISA cytokine measurement, single-cell RNA-seq confirming myeloid expression\",\n      \"pmids\": [\"41624837\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling pathway by which PRKACB suppresses cytokine release not defined\", \"Single knockdown approach without rescue or in vivo corroboration\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identification of direct PRKACB–RhoA interaction and Ser188 phosphorylation resolved a long-standing question of how PKA suppresses RhoA-driven metastasis, and showed that common DGC-associated RhoA mutations evade this phosphorylation.\",\n      \"evidence\": \"Co-IP, GST pull-down, proximity ligation assay, in vivo peritoneal metastasis model in mice\",\n      \"pmids\": [\"41851075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRKACA also phosphorylates RhoA S188 with comparable efficiency not compared\", \"Whether therapeutic reactivation of PRKACB–RhoA signaling is feasible in DGC is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the non-redundant roles of PRKACB versus PRKACA in specific tissues, the structural basis for isoform-specific holoenzyme assembly, and whether PRKACB directly phosphorylates tau or acts through intermediate kinases in neurodegeneration.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No systematic comparison of Cα versus Cβ substrate specificity in vivo\", \"No high-resolution structure of Cβ in complex with type I regulatory subunits\", \"Direct versus indirect role in tau phosphorylation not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 8, 12]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 8, 9, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 6, 7, 8, 9, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 13]}\n    ],\n    \"complexes\": [\n      \"PKA holoenzyme (type I and type II)\",\n      \"RyR2/FKBP12.6/PKA/mAKAP macromolecular complex\"\n    ],\n    \"partners\": [\n      \"PRKAR1A\",\n      \"PRKAR1B\",\n      \"RHOA\",\n      \"RYR2\",\n      \"FKBP1B\",\n      \"TAL1\",\n      \"CREB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}